Jeannie Hoffman-Censits

14PUBLICATIONS
138CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Oct 13, 2026
Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab.

|Jun 26, 2026
Peripheral Th17 Immune Signature Associates with Excellent Response to Anti-PD-1/Anti-PD-L1 Therapy across Solid Tumors.

|Apr 19, 2026
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.

|Jan 07, 2026
Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.

Akhilesh Mishra, Ajay Kumar Sharma, Kuldeep Gupta

|Nov 03, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.

David H Aggen, Meredith McKean, Jean H Hoffman-Censits

|Sep 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

Pageof 3

Frequent Collaborators

4 joint publications

Noah M Hahn

4 joint publications

Burles Avner Johnson

3 joint publications

Evan J Lipson

3 joint publications

Mari Nakazawa